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Abstract: Immunoglobulin A (IgA) plays a key role in defending mucosal surfaces against attack by
infectious microorganisms. Such sites present a major site of susceptibility due to their vast surface
area and their constant exposure to ingested and inhaled material. The importance of IgA to effective
immune defence is signalled by the fact that more IgA is produced than all the other immunoglobulin
classes combined. Indeed, IgA is not just the most prevalent antibody class at mucosal sites, but is
also present at significant concentrations in serum. The unique structural features of the IgA heavy
chain allow IgA to polymerise, resulting in mainly dimeric forms, along with some higher polymers,
in secretions. Both serum IgA, which is principally monomeric, and secretory forms of IgA are
capable of neutralising and removing pathogens through a range of mechanisms, including triggering
the IgA Fc receptor known as FcαRI or CD89 on phagocytes. The effectiveness of these elimination
processes is highlighted by the fact that various pathogens have evolved mechanisms to thwart such
IgA-mediated clearance. As the structure–function relationships governing the varied capabilities of
this immunoglobulin class come into increasingly clear focus, and means to circumvent any inherent
limitations are developed, IgA-based monoclonal antibodies are set to emerge as new and potent
options in the therapeutic arena.
Keywords: immunoglobulin A; IgA; structure; FcαRI; CD89; immune evasion; therapeutic antibodies
1. Introduction
The human immune system expends a considerable amount of energy in production of
immunoglobulin A (IgA), since more IgA is made than all the other classes of immunoglobulin
(Ig) combined. IgA is present in both serum, where at 2–3 mg/mL it is the second most prevalent
circulating Ig after IgG, and in external secretions such as those that bathe mucosal surfaces, where
it is the predominant Ig. It has been calculated that around 60 mg of IgA is produced per kilogram
of body weight per day in the average human [1,2], much of it being localised at mucosal surfaces.
Such surfaces, which collectively have a surface area in adult humans of around 400 m2 [3], are major
sites of vulnerability, given their exposure to the environment, and IgA clearly plays a critical role in
their protection against attack by invading pathogens.
In humans, there are two subclasses of IgA, named IgA1 and IgA2. Like all Ig, each subclass
comprises a basic molecular unit of two identical heavy chains (HCs) and two identical light chains
(LCs). Each chain begins at its N-terminus with a variable region, which is followed by a constant
region. The LCs are the same in each subclass, but the HCs differ within their constant regions, which
are encoded by distinct Cα genes. Two allotypic variants of human IgA2, known as IgA2m(1) and
IgA2m(2), have been characterised. A third IgA2 variant, termed IgA2(n), has been described [4],
but while presumed to be an allelic form, its penetrance in the population remains to be investigated.
Unlike other Ig classes, IgA exists in multiple molecular forms. In human serum, the predominant
IgA form is monomeric, i.e., comprises 2HC and 2LC, with a subclass distribution of about 90% IgA1
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and 10% IgA2. In contrast, the main molecular form found at mucosal surfaces, known as secretory IgA
(SIgA), is dimeric, although some higher molecular weight species, including trimers and tetramers,
are also present. Here the relative proportion of the two subclasses is more closely matched; an average
distribution being about 40% IgA1 and 60% IgA2, though this varies depending on the particular
mucosal site sampled.
Genetic sequence analysis has confirmed the presence of IgA in all categories of mammals
(placental, marsupials, and monotremes) and in birds. However, there are notable species differences.
Most mammals have a single IgA isotype. IgA1 and IgA2 subclasses akin to those in humans are only
present in related primates, including chimpanzees, gorillas, and gibbons [5], consistent with IgA1
arising relatively recently in evolutionary terms. Orangutans have an equivalent of IgA1, but appear
to have lost their form of IgA2. The other group of mammals to have more than one IgA are rabbits
and other lagomorphs, which have a massively expanded number of IgA genes, resulting in 14 known
subclasses, 11 of which are expressed. A 15th IgA was recently described in domestic European
rabbits [6]. While IgA is known to play a common role in protection at mucosal surfaces [7], the levels,
forms, and distribution of IgA vary. For example, in species commonly used in experimental research,
including mice, rats, and rabbits, the main form of IgA in serum is dimeric rather than the monomeric
form seen in humans. In these same species, unlike humans, the main source of IgA in the gut lumen is
from bile. Another species difference relates to the prevalent Ig found in colostrum and milk. While in
humans this is IgA, in cows, sheep, goats, and horses, the main immunoglobulin isotype present is IgG.
Such species differences have tended to constrain research on the general features of IgA, and mean
that there are inherent problems with extrapolation of results on IgA from animal models to humans.
This review will focus primarily on human IgA, and will explore structure and function relationships
and the prospect for developing IgA-based therapeutic monoclonal antibodies (mAb). The issue of
species differences within the IgA system remains of relevance, given the growing interest in IgA as a
potential therapeutic option and the requirement for meaningful models to robustly assess capabilities
in this context.
2. IgA structure
2.1. General Features
In common with other Igs, both the HCs and LCs of IgA are folded into a number of variable
(V) and constant (C) domains, each encoded by a separate exon. These number four in the HC
(namely VH, Cα1, Cα2, and Cα3, starting from the N-terminus) and two in the LC (namely VL and
CL, from the N-terminus). Each domain folds into a similar globular secondary structure, known
as the immunoglobulin fold, a feature of all Igs. Typically stretching some 110 amino acids, each
domain comprises two β-sheets made up of anti-parallel β-strands, which sandwich together around a
stabilising disulphide bond.
Interposed between the Cα1 and Cα2 domains of each HC lies a flexible hinge region, which is
particularly extensive in human IgA1 but shorter in human IgA2. Indeed, the hinge is the region of
greatest difference between the two subclasses. Unlike IgG, there are no interchain disulphide bridges
within the hinge region, which presumably affords the IgA hinge sequences, particularly the longer
ones of IgA1, the ability to flex independently of each other, but may also increase the susceptibility
to proteolysis.
The hinge of IgA1, rich in proline, serine, and threonine, contains a sequence missing in IgA2 that
comprises two eight amino acid repeats (Figure 1). The hinge in human IgA is encoded in a sequence
present at the 5′ end of the exon encoding the Cα2 domain, rather than by a separate exon or exons as
seen for IgG. As in other Igs, the hinge affords flexibility to the whole IgA molecule that is critical for
activity. It varies considerably in length and sequence between IgAs from different species (Figure 1).
At the C-terminus of the IgA HC lies an 18 amino acid extension known as the tailpiece. While a
corresponding feature is lacking in IgG and IgE, a highly similar sequence is found at the C-terminus
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of the HC of IgM. For both IgA and IgM, the tailpiece is crucial to the Ig’s ability to polymerise into
primarily dimers and pentamers, respectively.Antibodies 2019, 8, x FOR PEER REVIEW 3 of 30 
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(comprising two Cα2 and two Cα3 domains), responsible for triggering elimination processes (Figure 
2). The interaction between chains is stabilised by disulphide bonds between the HCs and LCs within 
the Fab region and between the two HCs at the Cα2 domains, and by close pairing of opposing 
domains: VH with VL, Cα1 with CL, and one Cα3 domain with the other one. Such pairing relies on 
an array of non-covalent interactions, chiefly hydrogen bonds and van der Waals contacts, between 
the domains involved.  
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Figure 1. Hinge sequences of IgAs from different species. Numbers following the species name indicate
the IgA subclass, and allotype where appropriate. Amino acid numbering above human IgA1 is
according to the commonly adopted scheme used for IgA1 Bur [8].
Two HCs and two LCs are organised into two Fab regions (each comprising VH, Cα1, VL,
and CL domains), responsible for binding to antigen, linked via the hinge region to a single Fc region
(comprising two Cα2 and two Cα3 domains), responsible for triggering elimin ti n proce ses (Figure 2).
The interaction between chains is stabilised by di ulphide bonds between the HCs and LCs within
the Fab region and between the two HCs at the Cα2 domains, and by close pairing of opposing
domains: VH with VL, Cα1 with CL, and one Cα3 domain with the other one. Such pairing relies on
an array of non-covalent interactions, chiefly hydrogen bonds and van der Waals contacts, between the
domains involved.
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Figure 2. Schematic diagram of IgA structures eric, dimeric, and s cretory IgA. In IgA1, the
heavy chain domains are in blue, and those of t t chains in yellow. n IgA2, the heavy chain
domains are in red, and the light chain domains in yellow. The tailpieces are shown as extensions to the
C-termini of the Cα3 domains in the monomeric forms. Dimeric and secretory forms of IgA2 are not
depicted. J chain, which is present in both dimeric and secretory IgA, is shown in cyan. The domains
of secretory component, derived from the extracellular region of pIgR, are present in secretory IgA and
are shown in orange.
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The Cα2 domains do not form a close pair, but instead have N-linked oligosaccharides that
overlie the surfaces normally involved in pairing. N-linked oligosaccharides in fact make rather a
significant contribution of the total mass of IgA, accounting for 6–7% of the mass of human IgA1,
and 8–10% of the mass of human IgA2 [9]. The aforementioned Cα2 domain sugars are found in both
IgA1 and IgA2, attached to residue Asn263. Both subclasses have another N-linked sugar attached
to the tailpiece at residue Asn459. Recently, it has been reported that the glycans attached at Asn459
can interact directly with certain viruses and thereby neutralise them [10]. Human IgA2 has further
N-linked sugars attached at residues Asn166 in the Cα1 domain and Asn337 in the Cα2 domain.
IgA2 molecules of the IgA2m(2) allotype have a further N-linked sugar attached at Asn211 in the Cα1
domain. In terms of composition, the N-linked sugars of serum and secretory IgA comprise a family of
related structures centred on a biantennary mannosyl chitobiose core, with a small proportion being
more branched, mostly with triantennary structures. Fucosylation level varies, as does the numbers of
sugars (galactose and sialic acid) found at the branch termini (Figure 3) [11–13]. Further glycosylation
complexity arises through the attachment of usually between 3 and 6 core 1 and/or Tn O-linked sugars,
composed principally of N-acetyl galactosamine, galactose, and sialic acid, to the hinge of IgA1 [12,13].
These O-linked glycans introduce further heterogeneity, since they consist of a family of structures,
varying in terms of the presence or absence of sialic acid and galactose.
Antibodies 2019, 8, x FOR PEER REVIEW 4 of 30 
 
domains are in red, and the light chain domains in yellow. The tailpieces are shown as extensions to 
the C-termini of the Cα3 domains in the monomeric forms. Dimeric and secretory forms of IgA2 are 
not depicted. J chain, which is present in both dimeric and secretory IgA, is shown in cyan. The 
domains of secretory component, derived from the extracellular region of pIgR, are present in 
secretory IgA and are shown in orange. 
The Cα2 domains do not form a close pair, but instead have N-linked oligosaccharides that 
overlie the surfaces normally involved in pairing. N-linked oligosaccharides in fact make rather a 
significant contribution of the total mass of IgA, accounting for 6–7% of the mass of human IgA1, and 
8–10% of the mass of human IgA2 [9]. The aforementioned Cα2 domain sugars are found in both 
IgA1 and IgA2, attached to residue Asn263. Both subclasses have another N-linked sugar attached to 
the tailpiece at residue Asn459. Recently, it has been reported that the glycans attached at Asn459 can 
interact directly with certain viruses and thereby neutralise them [10]. Human IgA2 has further N-
linked sugars attached at residues Asn166 in the Cα1 domain and Asn337 in the Cα2 domain. IgA2 
molecules of the IgA2m(2) allotype have a further N-linked sugar attached at Asn211 in the Cα1 
domain. In terms of composition, the N-linked sugars of serum and secretory IgA comprise a family 
of related structures centred on a biantennary mannosyl chitobiose core, with a small proportion 
being more branched, mostly with triantennary structures. Fucosylation level varies, as does the 
numbers of sugars (galactose and sialic acid) found at the branch termini (Figure 3) [11–13]. Further 
glycosylation complexity arises through the attachment of usually between 3 and 6 core 1 and/or Tn 
O-linked sugars, composed principally of N-acetyl galactosamine, galactose, and sialic acid, to the 
hinge of IgA1 [12,13]. These O-linked glycans introduce further heterogeneity, since they consist of a 
family of structures, varying in terms of the presence or absence of sialic acid and galactose. 
 
Figure 3. Schematic structures of IgA (A) N-linked and (B) O-linked glycan side chains. Structure (A) 
occurs in both IgA1 and IgA2, while structure (B) is present only attached to the hinge region of IgA1. 
NeuNAc, N-acetyl neuraminic (sialic) acid; Gal, galactose; GlcNAc, N-acetyl glucosamine; Man, 
mannose; Fuc, fucose; GalNAc, N-acetyl galactosamine. ±Gal, ±NeuNAc, or ±Fuc indicate that some 
chains terminate at the preceding sugar. 
2.2. IgA Fab Region 
In terms of structural components unique to IgA, within the Fab region it is the Cα1 domain that 
constitutes the IgA-specific component, with the VH, VL, and CL being common to other Ig classes. 
Solved X-ray crystal structures of the Fab regions of mouse IgA myeloma proteins have provided 
earlier structural insights. From two different plasmacytoma IgAs, the elbow bend angle between the 
VH and Cα1 domains was seen to range between 133 and 145°, suggesting a degree of flexibility 
within the Fab region [14,15]. However, more recently, the crystal structure of a human IgA1 Fab has 
been determined at high resolution [16]. The position of the disulphide between the LC and HC, 
together with the markedly hydrophobic interface between the VH and Cα1 domains, appears to 
Figure 3. ti t t r s f I ( ) -li ( ) -li l si c i s.
occ rs t IgA1 and IgA2, while structure (B) is present only attached to the hin e region of
IgA1. Neu Ac, N-acetyl neuramin c (siali ) acid; Gal, galactose; GlcNAc, N-acetyl glucosa i e;
annose; Fuc, fucose; GalNAc, N-acetyl galactosamine. ± al, ± , r i t t so e
chains ter inate at the preceding sugar.
2.2. IgA Fab Region
In terms of structural components unique to IgA, within the Fab region it is the Cα1 domain that
constitutes the IgA-specific component, with the VH, VL, and CL being common to other Ig classes.
Solved X-ray crystal structures of the Fab regions of mouse IgA myeloma proteins have provided
earlier structural insights. From two different plasmacytoma IgAs, the elbow bend angle between the
VH and Cα1 domains was seen to range between 133 and 145◦, suggesting a degree of flexibility within
the Fab region [14,15]. However, more recently, the crystal structure of a human IgA1 Fab has been
determined at high resolution [16]. The position of the disulphide between the LC and HC, together
with the markedly hydrophobic interface between the VH and Cα1 domains, appears to constrain the
IgA1 Fab, making it somewhat rigid. When compared to a matched IgG featuring the same VH and
VL domains, the IgA1 Fab exhibited a difference of about 5◦ in the elbow angle from that in IgG. It has
been suggested that the greater rigidity inherent in IgA1 Fab may exert subtle allosteric effects on the
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antigen binding site with resultant impact on antigen binding affinity. Such considerations are relevant
to engineering of therapeutic antibodies, and are explored in depth elsewhere [17].
The IgA subclasses differ in the arrangement of their interchain disulphides, including those
between LC and HC within the Fab region. While IgA1 and IgA2(m)2 have the usual disulphide
bridges between HC and LC, these are located at different positions—between a common Cys in LC
and Cys133 in IgA1 HC and Cys220 in IgA2m(2) HC. These HC Cys are located close to the VH–Cα1
interdomain region and at the C-terminal end of the Cα1 domain (penultimate residue), respectively.
Remarkably, in IgA2m(1), such HC–LC disulphides are generally lacking. Instead, disulphide bridge
links the two LCs, and the association between HC and LC is stabilised by non-covalent interactions.
2.3. IgA Fc Region
Turning to the Fc region, important structural information has been gained from the solved X-ray
crystal structures of human IgA1 Fc in complex with the extracellular domains of FcαRI [18] and with
the staphylococcal protein SSL7 (Figure 4) [19]. In terms of overall configuration, the structure of the
Fc region is similar to that of IgG and IgE, but there are important distinctions. Notably, the location of
the disulphide bridges between the two HCs, and the attachment sites and positions of the N-linked
glycans are different in IgA from these other Ig classes.
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(Figure 2). Thus, Cys242 in each HC can link to Cys299 in the opposit HC. Further disulphide
bonds are presumed to exist, for example, between Cys241 in each HC, or between Cys299 in each HC,
or between Cys241 in one HC and Cys301 i the other, but the trunca ed fo ms of IgA1 Fc used in
crystallisation did no allow direct resolution of these.
t this potentia ly le s stable scenario is avoided to some extent due to ttachment of
N-linked glycans at Asn263. The sugar moieties attached a this site lie over the o ter f
, 2 .
The 18 amino acid tailpiece at the C-terminus of each HC was missing from the IgA1 Fc fragments
used for crystallisation, and hence no information on its structure was obtained. Recently it has been
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modelled to occupy a range of conformations [20]. The tailpiece carries a cysteine residue at position
471, and the potential linkages that this cysteine residue may make with other “free” Cys residues in
IgA remains somewhat of an enigma.
2.4. Structure of Monomeric IgA
As with other Igs, the inherent flexibility of intact monomers of IgA tend to frustrate crystallisation
efforts. Thus, in order to probe the conformation of entire IgA monomers rather than the separate Fab
and Fc regions, lower resolution techniques, including electron microscopy (EM), and more recently,
X-ray and neutron scattering of IgA in solution, have been used. These have been useful in predicting
the overall dimensions of IgA molecules, and have led to an understanding that the IgA1 has a greater
average Fab centre to Fab centre distance than IgA2: 16.9 nm for IgA1 compared with just 8.2 nm for
IgA2 [21–26].
Models arising from solution scattering studies originally suggested that both human IgA
subclasses adopt average T-shaped structures (Figure 5), which presumably reflected averages of the
different conformations available to these molecules as a result of flexibility. Indeed, more recent work
using these techniques has reported IgA1 to have an extended Y-shaped structure, with the Fab regions
positioned well away from the Fc, in keeping with previous electron micrographs. Given the major
advances made in recent years in cryogenic electron microscopy (cryo-EM), it can be envisaged that
definitive understanding of the structure of monomeric IgA is likely to emerge from this technique.
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2.5. Dimeric IgA
The IgA destined for the mucosal surfaces is produced locally to the mucosa in polymeric
form. These are principally dimers comprising two IgA monomers covalently linked to an additional
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polypeptide known as joining chain or J chain. J chain is a 15 kDa polypeptide, expressed by
antibody-producing cells, and is also present in larger IgA polymers and pentameric IgM. It is
incorporated into polymeric IgA or IgM prior to secretion [27]. In the case of IgA, marginal zone B and
B-1 cell-specific protein (MZB1) has been shown to promote J chain binding to IgA in plasma cells [28].
J chain is very highly conserved across species (mammals, birds, reptiles, fishes, and amphibian) and is
not known to resemble any other protein. It has one N-linked glycan attached at Asn48 which exists in
five major forms, principally sialylated biantennary complex structures [13]. J chain’s ability to join
HCs in polymeric Igs relies on two key Cys residues, from amongst the eight cysteines it possesses.
Six of the eight are involved in interchain disulphide bridges (Cys12–Cys100, Cys17–Cys91, and
Cys108–Cys133) [29,30]. Presently, the three-dimensional structure of J chain is unresolved. Models
have tended to favour a two-domain structure [30,31].
Early studies of dimeric IgA structure utilised EM to view myeloma IgA preparations. It was seen
to have a double-Y shape, in which the Fc regions joined to each other via their C-terminal regions.
The length of the joined Fc region was in the range 125–155 Å, consistent with two Fc regions of about
65 Å long being arranged end-to-end (Figure 2). The J chain is interposed between the two Fc regions,
and links to each of the monomers through disulphide bridges formed between the penultimate
Cys residues of the tailpieces (Cys471) and the two J chain cysteines alluded to above (Cys14 and
Cys68). The critical roles played by these cysteines in the linkage has been verified through targeted
mutagenesis of both the tailpiece and J chain [32,33]. In keeping with these observations, solution
structure analysis of dimeric IgA1 have predicted a near-planar structure with end-to-end Fc contacts,
although in this study, the J chain structure and orientation used in the modelling was arbitrary [34].
Further analysis, possibly from techniques such as cryo-EM, will be necessary to provide an in-depth
view of the relative arrangement of Fc regions and J chain.
2.6. Secretory IgA
In external secretions, the predominant form of IgA is SIgA, which derives from local synthesis by
Ig-producing cells in organised mucosal-associated lymphoid tissues, most of which are committed to
the IgA isotype. SIgA is mostly in dimeric form, with some tetramers also being present. The relative
proportions of each varies from mucosal site or secretion. For example, in saliva and milk, the ratio of
dimeric/tetrameric SIgA is around 3:2. Secretions can also contain some monomeric IgA, but again, the
amounts vary. In saliva and milk, about 5–10% of the IgA is monomeric, whereas in cervical fluid, a
much higher proportion can be present [35].
Another factor accounting for the high relative concentration of IgA in secretions is the presence
of a receptor known as the polymeric Ig receptor (pIgR), which mediates the specific transport of
polymeric Igs across the mucosal epithelium into the secretions (Figure 6). pIgR is expressed on the
basolateral surface of epithelial cells lining mucosal sites, and binds and transports only polymeric
Igs. At mucosal surfaces, the predominant ligand is dimeric IgA, since the larger size of IgM restricts
diffusion from serum, and hence, the smaller, and locally-produced, dimeric IgA is preferentially
transferred [36].
pIgR is a single polypeptide receptor, comprising a ~620 amino acid extracellular portion which
folds up into five Ig-like domains with particular homology to Ig variable domains, a 23 amino acid
transmembrane section, and an internal tail of around 103 amino acids [37]. The extracellular domains,
named D1–D5 from the N-terminus, are each stabilised by one or more internal disulphide bridges,
and are decorated by seven N-linked glycans. Between the end of D5 and the membrane lies a short
stretch of non-Ig-like sequence.
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Transport of dimeric IgA across the epithelium (transcytosis) involves its binding to pIgR at
the basolateral surface of the epithelial cell, followed by internalisation and transport via vesicular
compartments to the apical surface of the cell (Figure 6). During the process, pIgR is cleaved between
D5 and the membrane to release a major fragment of the receptor referred to as secretory component
(SC). A disulphide bridge forms between SC and dimeric IgA, and when the complex is released at the
apical surface, SC remains as part of the released IgA, then known as SIgA. EM studies of SIgA from
colostrum show a double Y-shaped configuration.
Domains D1–D3 of pIgR are known to play critical roles in binding to dimeric IgA, with domains
D4 and D5 also making smaller contributions. In particular, loops lying at the end of D1, akin to the
complementarity determining regions (CDR) of variable domains, are central to the binding and are
known to lie close to each other based on the solved X-ray crystal structure of the domain [38–40].
Residues in CDR1, CDR2, and CDR3 have been implicated in the binding to dimeric IgA [37].
Turning to the elements of dimeric IgA involved in the interaction, it is believed that the initial
interaction involves engagement of D1 of pIgR with an exposed loop (residues 402–410) and other
close lying residues (Phe411, Val413, Thr414, Lys377) on the Cα3 domain of IgA, along with a region on
the Cα2 domain (Pro440–Phe443) lying at the Cα2–Cα3 domain interface (Figure 4) [41–43]. Thereafter,
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a disulphide bound formed between one of two cysteine residues in D5 of pIgR (Cys468 or Cys502)
and Cys311 in the Cα2 domain of IgA anchors SC and dimeric IgA together [44]. It has also been
demonstrated that direct interactions between J chain and pIgR occur [45].
More recently, the structure of free SC has been elucidated by X-ray crystallography and shown to
adopt a triangular arrangement, with a large interface between domains D1, D4, and D5, which buries
some 1480 Å2 of surface area from solvent contact (Figure 7) [46]. The five domains lie in a plane,
giving the triangle shape a thickness similar to that of a single domain (about 40 Å). To further explore
SC structure and its relationship to function, the same study used double electron–electron resonance
spectroscopy on spin-labelled variants of SC in solution as a means to explore the flexibility of the
protein domains. This analysis confirmed the crystal structure to represent the predominant solution
structure of free SC at the D1–D5 interface. However, when the spin-labelled SC was incubated with
dimeric IgA, a dramatic separation of D1 and D5 was apparent, consistent with an increase in distance
of more than 42Å between these domains, resulting in a final separation of more than 85 Å. Analysis of
the binding characteristics of shortened constructs of SC supported the key role of D1 in binding to
dimeric IgA and indicated a role for D5 in mediating non-covalent interactions with dimeric IgA [46].
The results also suggest that D2, and possibly D3, contribute to binding either directly or through
promoting interactions between D5 and dimeric IgA. Thus, we are left with a current model that
involves opening up of the pIgR extracellular structure upon binding to SIgA, with initial contact
through D1, but later involvement of the other pIgR domains. The final separation of D1 and D5 would
be sufficient to allow engagement of D1 and D5 with domains in the same IgA monomer or across the
two different IgA monomers present in the dimer.
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3. IgA Function
3.1. Neutralisation
Through direct engagement of their antigen binding sites with antigens on pathogens,
IgA molecules neutralise or block the activity of a range of viruses, bacteria, and protozoa, and prevent
their attachment to host cells [47]. Similarly, binding of IgA to pathogenic products such as toxins can
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neutralise their activity and prevent the disease symptoms associated with them [48]. The attachment of
several types of pathogenic microorganisms to the mucosal surfaces can be prevented by the interaction
of the glycans on IgA with sugar-dependent receptors or fimbriae on their surfaces [10,49–51]. Thus,
IgA contributes to immune exclusion, a process by which the adsorption of pathogens to mucosal
surfaces is prevented through agglutination, such that the aggregates formed are unable to penetrate
though the mucus that lines mucosal surfaces. The multiple antigen binding sites of SIgA enable both
high avidity binding and crosslinking of particulate matter, resulting in efficient blocking activity.
Moreover, IgA can interact with other innate defence factors in mucosal secretions to enhance immune
protection. These include mucins [52,53], lactoferrin, and the lactoperoxidase system [54].
In vitro studies suggest that mucosal IgA can also mediate protective functions during its passage
through the epithelium or by carrying pathogens or their products encountered on the basolateral side
of the epithelium out across the epithelium (Figure 6) [55]. The latter reflects the fact that pIgR can
transport dimeric IgA alone or in complex with antigen. This mechanism can drive removal or excretion
of soluble antigens from various origins, as well as viral particles [56]. Antigen-specific dimeric IgA has
been seen in vitro to neutralise endocytosed bacterial lipopolysaccharide (LPS) within epithelial cells,
whilst undergoing pIgR-mediated transcytosis. Following colocalisation within the apical recycling
compartment, the IgA was able to prevent the proinflammatory events usually triggered by LPS [57].
Similarly, while undergoing epithelium transcytosis, dimeric IgA targeted to certain viruses have
been able to block viral growth, seemingly following intersection of the IgA and viral proteins in the
apical recycling endosomes. Such effects have been reported for Sendai virus [58], influenza virus [59],
measles virus [60], rotavirus [61,62], and HIV [63,64]. However, questions remain as to whether these
processes reflect the situation in vivo, although experiments in mouse models suggest that there may
be some physiological relevance [65,66].
3.2. Complement Activation
IgA lacks the site for C1q binding present in IgG and does not bind C1q, and therefore is not
expected to activate the classical pathway of complement. Interestingly, a recent study looking at
complement-dependent cytotoxicity of B cells by CD20-specific IgA suggested that complement
was activated by IgA. However, in vivo, the activity of the anti-CD20 IgA to deplete B cell targets
was not abrogated in C1q- or C3-deficient mice, suggesting that complement activation was not the
predominant killing mechanism in action [67]. The ability of IgA to activate the alternative pathway of
complement has been somewhat contentious, but the prevailing view is that the reported activation is
likely via the lectin pathway as a result of binding to mannose-binding lectin [68]. However, the ability
to activate via this route is likely dependent on glycosylation status.
3.3. Interaction of the IgA Fc Region with Host Receptors
In addition to the above-mentioned functions, IgA mediates a variety of effector functions through
interaction with a number of different host receptors expressed on various cell types. The interaction
with pIgR and the resultant transport into mucosal secretions has already been discussed. Now,
we will turn to consideration of the IgA-specific receptor FcαRI, a key means by which IgA can trigger
clearance mechanisms against invading pathogens. Other receptors which have been described to
have specificity for IgA are generally less well characterised in terms of their roles and will not be
addressed further here. These include Fcα/µR, which exhibits specificity for polymeric forms of
IgA and IgM, in the case of IgA through a site at the Cα2–Cα3 domain interface [69]; transferrin
receptor (CD71), which has been implicated in retrograde transfer of SIgA immune complexes back
through the epithelium [70]; a microfold (M) cell receptor, possibly Dectin-1, which may mediate
reverse transcytosis of SIgA immune complexes through M cells [71]; dendritic cell (DC)-specific
intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN), which appears to take up SIgA
immune complexes into sub-epithelial dendritic cells [72]; the inhibitory IgA receptor Fc receptor-like
4 (FcRL4) thought likely to be important for immune complex-dependent regulation of B cells [73];
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the asialoglycoprotein receptor (ASGPR) on hepatocytes, which mediates clearance of IgA from the
circulation [74]; β-1,4-galactosyltransferase 1, which, along with CD71, has been identified as a potential
IgA receptor on kidney mesangial cells [75]; and lastly, the putative receptor for SC and SIgA on
eosinophils [76].
3.4. FcαRI
Although a less closely related member, FcαRI belongs to the Ig Fc receptor family, which also
features specific receptors for IgG (FcγRI, FcγRII and FcγRIII) and IgE (FcεRI) [77–79]. It is expressed
on neutrophils, eosinophils, monocytes, macrophages, Kupffer cells, and some DC subsets. Also known
as CD89, it is encoded by a gene lying on chromosome 19, within the leukocyte receptor cluster
(LRC) close to killer cell immunoglobulin-like receptors (KIR) and leukocyte immunoglobulin-like
receptors (LILR) receptors. In contrast, other Fc receptors in the family are clustered on chromosome 1.
In keeping with this gene location, FcαRI shares closer amino acid similarity with LRC members than
with the IgG and IgE Fc receptors.
FcαRI is organised into two extracellular Ig-like domains, a transmembrane segment, and a
short cytoplasmic tail devoid of signalling motifs. It associates with a dimer of the FcR γ chain,
a short transmembrane polypeptide originally characterised as a component of the IgE receptor,
FcεRI. The γ chain carries two immunoreceptor tyrosine-based activation (ITAM) motifs within its
cytoplasmic region, important for signalling to the cell interior upon receptor crosslinking by binding
to IgA-containing immune complexes or to IgA concentrated on a pathogen surface. The outcome
of such signalling can be a range of responses depending on the cell involved, from phagocytosis,
superoxide generation (respiratory burst), release of cytokines, chemoattractants, or inflammatory
mediators, through to release of neutrophil extracellular traps (NET) [80,81]. On the other hand,
binding of monomeric IgA to FcαRI has been reported to trigger inhibitory signals via the γ chain
ITAM as opposed to the aforementioned activatory ones. Such inhibitory ITAM (ITAMi) signalling is
considered to dampen down excessive IgA immune complex-mediated responses. The underlying
signalling processes and the specifics of responses are detailed elsewhere [82].
Alternatively spliced isoforms of FcαRI exist, with those known as a.1 and a.2 being expressed
on phagocytes [83,84]. The a.1 version has a molecular weight of 55–75 kDa on neutrophils and
monocytes, while additional glycosylation renders it a little heavier (70–100 kDa) on eosinophils.
The a.2 version is lacking 22 amino acids from the second extracellular domain, and is only present on
alveolar macrophages. In terms of allelic variation, a common, nonsynonymous, single nucleotide
polymorphism (SNP) has been described in the coding region of FcαRI, which results in a change of
residue 248 from Ser to Gly within the cytoplasmic domain [85].
The structure of the ectodomains of FcαRI has been solved at high resolution, in complex with the
Fc region of IgA1 [18]. The globular extracellular domains lie at an angle of around 90◦ to each other,
and it is notable that their relative orientation is very different from the corresponding domains of
other Fc receptors [18,86].
FcαRI binds both subclasses of human IgA with similar affinity, and also engages both serum IgA
(monomeric) and SIgA (polymeric), albeit with some differences in outcome [82]. However, it has been
observed on polymorphonuclear leukocytes that SIgA cannot bind to FcαRI in the absence of CR3 or
Mac-1 [87]. The affinity of FcαRI for IgA molecules in solution is low (Ka of approximately 10−6 M−1),
but IgA immune complexes, or IgA aggregated for example on a pathogen surface, bind with higher
avidity. The crystal structure of the complex of the ectodomains of FcαRI and IgA1 Fc revealed that
each IgA Fc region is capable of binding two FcαRI molecules [18]. The physiological relevance of this
observed stoichiometry is a subject of some conjecture. The site of interaction on IgA, originally defined
by mutagenesis [88–90] and further defined by crystallography [18], lies at the Fc domain interface,
with important contributions from Cα2 residues Leu257 and Leu258 and Cα3 residues Met433, Leu441,
Ala442, Phe443, and the aliphatic portion of Arg382 (Figure 4). On the receptor, the hydrophobic
core of the interaction relies on contributions from a region in the membrane distal domain (Tyr53,
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Leu54, Phe56, Gly84, His85) with contributions also from Lys55 [18,91,92]. This mode of Fc receptor–Ig
interaction is very different from the FcγR–IgG and FcεRI–IgE interactions, which involve sites on the
upper reaches of the respective Fc regions, and on the membrane proximal domains of the respective
receptors [86].
The contribution of N-linked glycans, both on FcαRI and IgA, in the interaction have
been investigated. Studies using a glycoengineering approach to generate IgAs carrying distinct
homogeneous N-glycans have indicated that different glycoforms of IgA1 and IgA2 do not exhibit
radically different binding to FcαRI [20], in keeping with earlier analysis that showed that variation in
or lack of the N-linked glycans at Asn263 in the Cα2 domain did not significantly impact on binding to
FcαRI [12,93]. In contrast, specific N-linked sugar moieties on FcαRI have been shown to impact on
binding to IgA [20,94]. A FcαRI glycovariant with oligomannosidic N-glycans has been reported to
bind IgA 2–3 times more tightly than variants with complex N-glycans [20], while deglycosylation of
FcαRI at Asn58 has been shown to increase binding to IgA [94].
Recently, binding of FcαRI to IgA has been demonstrated to propagate conformational changes
within IgA as far as the hinge region [95]. Thus, FcαRI binding was shown not only to cause a decrease
in IgA Fc intradomain and interdomain flexibility, but also to impact on the hinge, such that binding of
lectins to the IgA1 hinge was affected.
It has been reported that peptide mimetics, consisting of either linear or cyclised peptides of 7–18
amino acids spanning regions of FcαRI or IgA known to be involved in the interaction site, may serve
as a means to inhibit IgA–FcαRI interactions [96]. Such peptides were shown to reduce IgA effector
functions mediated through FcαRI such as phagocytosis and production of activated oxygen species.
Blocking strategies based on peptides such as these, or on antibodies directed against FcαRI, have
been proposed as possible routes to prevent undesirable inflammatory conditions triggered through
aberrant IgA immune complexes [79,97].
Specific elements of the innate immune system are also known to interact directly with FcαRI and
impact on IgA binding. Thus, pentraxins such as C reactive protein and serum amyloid P component,
which adopt pentameric ring-like structures, have been shown to bind to FcαRI, in part, via a similar
region as IgA. Although the pentraxin interaction site on FcαRI appears to be more extensive than
that responsible for binding IgA, these acute phase proteins are able to competitively inhibit IgA
binding [98].
4. Circumvention of IgA Function by Pathogens
On the basis of phylogenetic and diversity analysis, the IgA–FcαRI interaction has been proposed
to be the focus of an evolutionary arms race between pathogens and humans [99,100]. The site on IgA
central to the interaction, which has been conserved in order to bind FcαRI, has been placed under
pressure to evolve by IgA binding proteins that certain pathogens produce. These IgA binding proteins
have evolved to interact with the same site, thereby subverting the IgA response, and driving an
iterative selective process in which both mammalian and pathogen proteins have continued to evolve
in an attempt to “outsmart” the other. In fact, targeting of the FcαRI interaction site is just one of the
strategies that pathogenic microorganisms have used to circumvent the protective capabilities of IgA.
The existence of different IgA-targeting mechanisms, together with the fact that these mechanisms
seem to have arisen independently in different organisms, suggests that they offer significant benefits
to microorganisms by allowing easier mucosal colonisation and spread. Examples include the IgA
binding proteins mentioned above and the production of enzymes that cleave and inactivate IgA,
which will be discussed in more detail below, and the generation of proteins that bind SC or pIgR and
aid adherence and invasion within the mucosae [101–104].
4.1. Bacterial IgA Binding Proteins
Certain important pathogenic bacteria, including Group A and B streptococci and Staphylococcus
aureus, express proteins on their surface, which bind specifically to IgA. Group A streptococci, which
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cause a range of diseases from mild skin and throat infections to life-threatening systemic conditions,
express Sir22 and Arp4, while group B streptococci, responsible for serious, sometimes deadly, infections
in new-born infants, express the unrelated β protein [105–107]. Staphylococcus aureus, which can cause
bacteraemia, infective endocarditis, and skin and soft tissue infections, expresses an IgA binding
protein known as Staphylococcal superantigen-like protein 7 (SSL7). Despite these proteins not being
related to each other, all bind at the Cα2–Cα3 interdomain region of IgA Fc at sites that overlap with
that for FcαRI [19,108,109]. They have been shown to competitively inhibit FcαRI binding; further,
the streptococcal proteins have been demonstrated to block triggering of elimination mechanisms via
FcαRI. Thus, these IgA binding proteins provide the bacteria in question with effective ways to evade
IgA-mediated clearance.
4.2. Bacterial Proteases That Target IgA
The protective capabilities of IgA can also be compromised through the actions of proteolytic
enzymes produced by a number of important pathogenic bacteria. These proteases all cleave in the
hinge region of IgA. With few exceptions, they act specifically on the extended hinge region of IgA1,
and do not cleave IgA2. Such IgA1 proteases are produced by bacteria responsible for infections of the
oral cavity, such as Streptococcus sanguis, Streptococcus mitis, and Streptococcus oralis, and of the genital
tract, such as Neisseria gonorrhoeae, suggesting that they afford an advantage to the bacteria in gaining a
foothold at mucosal surfaces. In addition, they are produced by bacteria responsible for meningitis
(Haemophilus influenza, Neisseria meningitidis, and Streptococcus pneumoniae).
The IgA1 proteases appear to have evolved several times over since those from different bacterial
species tend not to share common features. Indeed, they represent a range of protease types, with some
being metalloproteases, others being serine proteases, and yet others being cysteine proteases [110].
By separating the antigen-binding region of IgA from the Fc region critical for binding to host FcαRI,
IgA1 proteases perturb normal IgA-mediated protection mechanisms and leave the bacteria free to
proliferate [111].
Each IgA1 protease cleaves a specific site within the IgA1 hinge, either a Pro–Thr or a Pro–Ser
peptide bond (Figure 8). In order for IgA1 proteases to recognise the IgA1 hinge as a substrate, it has
become clear that not only sequence elements within the hinge itself are important [112,113], but,
at least for some IgA1 proteases, also specific regions of the IgA1 protein lying well beyond the hinge.
Thus, for efficient cleavage to occur, the susceptible bond is required to be positioned at a suitable
position relative to the Fc [114], and some proteases also require the presence of elements within the Fc
region of IgA1 [115,116]. Specifically, Cα3 domain residues Pro440–Phe443, which as mentioned above
form part of the interaction sites for FcαRI and pIgR, have been shown to be a requirement for cleavage
of IgA1 by the N. meningitidis type 2 IgA1 protease, while for the H. influenzae type 2 enzyme, different
Cα3 residues predicted to be involved in pIgR interaction are required for cleavage to proceed [116].
Echoing the case with IgA binding proteins, these requirements suggest that IgA1 proteases may have
commandeered conserved host receptor sites for their own benefit. One can envisage an interaction
between IgA1 protease and the IgA1 molecule as a whole, with the protease engaging with elements
within the Fc region as a means to stabilise a particular IgA conformation and aid positioning of its
active site next to the IgA1 hinge. Indeed, the solved X-ray crystal structure of an H. influenzae IgA1
protease is consistent with such a possibility [117].
A more detailed understanding of the molecular basis of IgA1 hinge cleavage by IgA1 proteases
may have therapeutic application. For example, following earlier work to identify possible inhibitors
for IgA1 protease [118,119], small molecule non-peptidic inhibitors for H. influenzae IgA1 protease
have recently been described in the first steps towards development of potential therapeutics for
antibiotic-resistant H. influenzae strains [120]. Further, it has been proposed that IgA1 proteases may
have utility as therapeutic options to degrade pathogenic immune complexes of aberrantly glycosylated
IgA1 in IgA nephropathy, a common cause of kidney disease [121,122].
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Figure 8. Amino acid sequence in the hinge region of human IgA1 and the cleavage sites of various
IgA1 proteases. The IgA1 hinge contains a duplicated octapeptide sequence that is missing in IgA2.
O-linked glycans are represented by yellow circles.
5. IgA Developability
Specific IgA is often found elevated in the serum and/or secretions after immunisation.
While vaccination via the systemic route tends to generate serum responses, vaccination through the
intranasal or oral route can elicit protective mucosal responses [123]. As a prime example, oral cholera
vaccination is well established as a means to induce protective mucosal IgA responses [124]. As another
example, studies in mice have shown that a nasal vaccine is sufficient to prevent Streptococcus pneumonia
colonisation, registering high levels of IgA and IgG in plasma and nasal washes. However, this
protective action was abrogated in IgA deficient mice [125]. In the context of viruses, neutralising IgA
antibodies against HIV can be found in the serum of survivors or vaccinated HIV patients [126,127],
and serum and salivary IgA against polio virus can be found elevated upon vaccination with live
attenuated viruses [128]. In mice, immun sation against reovirus has been demonstrated to lead to
an increase of serum and gut IgA, which pr ved to b essential to prevent reovirus infection [129].
A similar outcome was obs rved in mice immunised with influenza virus hemagglutinin, where the
induced IgA response provide protectio against influenza infection [130].
The above studies present a snaps ot of the protective rol that IgA can play against ba terial
or viral infection , b th in serum and mucosal secretio s. Since specific IgA c n clearly be beneficial
in clearing viral or bacteri l infections, passive admin stration of IgA is an a tractive option in cases
where the immune response is comprised or where insufficient time, or other logistical hurdles, prevent
generation of a timely robust response through active immunisation. Moreover, with regard to the
protection of mucosal sites, effective vaccination requires the correct antigen, adjuvant, and delivery
route to promote a robust and protective response. Hence, th u e of passive immunisation, by direct
delivery of specific antibodies, can prese t an alternative for the protection of mucos l surfaces.
How ver, t remains challenging to create a delivery route, especially for the gut mucosa.
5.1. Advantages of IgA-Based Therapeutics
The therapeutic antibody field is currently dominated by IgG-based mAbs. The advantages of
opening up this arena to include IgA-based mAbs are becoming increasingly apparent, piquing interest
in both academia and industry [79,131–133]. One advantage is the new prospects it offers in terms
of intellectual property, in what is already a complex landscape [134]. Secondly, as will be explored
further below, IgA mAbs are known to be highly effective at recruiting immune cells, and neutrophils
in particular, to deliver potent killing mechanisms, making the IgA–FcαRI axis an important target in
control of various cancers and infections. Such neutrophil-mediated tumour cell killing is considered
especially important for apoptosis-resistant cells [131]. Thirdly, IgA is likely to represent the most
suitable option for mucosal applications, given its prevalence and functional capabilities at such
sites. Fourthly, the structural distinctiveness of IgA, especially IgA1 with its ability to bridge greater
distances between antigens, may offer enhanced avidity in some scenarios. Fifthly, IgA can naturally
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polymerise into forms with enhanced agglutination capabilities, and which can be transported by
pIgR into mucosal secretions. Finally, it is possible to use components of IgA or IgA heavy chains in
combination with those of other Igs such as IgG, to explore new therapeutic possibilities.
5.2. Constraints of Using IgA Therapeutically and Efforts to Resolve These
Despite the numerous advantages that may be associated with the development of IgA in
the therapeutic setting, there are a number of constraints or limitations that need to be addressed.
For example, both pro-inflammatory and anti-inflammatory functions of IgA mediated through FcαRI
have been flagged up as being of relevance to the therapeutic potential of IgA [131,135]. As a result,
it will be important to establish the mechanism(s) at play in any particular treatment setting.
Another constraint is that IgA has a shorter half-life than IgG, estimated to be 4–6 days [136,137].
IgA cannot bind to the neonatal Fc receptor, FcRn, while engagement of IgG with this receptor results in
a half-life of about 21 days (although it varies with subclass). The short half-life of IgA would necessitate
much more frequent dosing if this class was to be used therapeutically. For example, in mouse tumour
models, it has been found to be necessary to give daily injections of IgA antibodies to reach effective
circulating concentrations [138]. Unless modified, use of IgA is therefore likely to be expensive and
less convenient for recipients because of the frequency of dosing. This shorter half-life is in part due
to clearance mediated by the ASGPR, which recognises terminal galactose residues on the glycans
of IgA. Efforts have been made to extend half-life by removing N-linked glycosylation sites [139],
generating IgA with higher terminal sialylation of N-glycans [140], by attaching an albumin-binding
domain to either the LC or HC in order to facilitate binding to the neonatal Fc receptor FcRn [141],
or by engineering in FcRn binding by generating an IgG–IgA Fc fusion [133].
A further constraint relates to efficiency issues in the expression, production, and purification
of recombinant IgA mAbs of a suitably homogeneous nature. It has long been recognised that IgA
production suffers from low expression levels and heterogeneous glycosylation. Systems enabling
increased expression of IgA have been developed [140,142,143], and advances in general expression
systems for other Igs are likely also to bring benefits [144,145]. There is interest in using plant-based
systems to express IgA [146–148], but the implications for glycosylation must be borne in mind,
especially since it is known that IgA glycosylation is impacted by expression system [149,150].
The logistics of working with IgA has been challenging due to the limited options for specifically
purifying this Ab class. Jacalin, a lectin that binds to the O-linked sugars on the IgA1 hinge, and light
chain binding protein-based strategies offer rather limited possibilities. Immobilised bacterial IgA
binding proteins, or peptides derived from them, represent a feasible solution [151,152], and IgA-binding
peptides selected from random peptide libraries may also have applicability in IgA purification [153].
The susceptibility of IgA1 to cleavage by IgA1 proteases may be another potential constraint to
its use. However, as discussed above, mutagenesis analysis has demonstrated how this might be
overcome either by engineering of the hinge itself or of the Fc region [116].
Another area for consideration in the design of therapeutic IgA mAbs are the routes to ensure
complete assembly. For instance, the disulphide bridge complexity in IgA2 presents challenges [154].
The production of polymeric forms of IgA or SIgA is particularly complex, given the requirement to
co-express LC, HC, and J chain, and ensure attachment of SC. However, systems to achieve this have
been explored and continue to be refined [133,155,156].
A final constraint to the development of therapeutic IgA mAbs stems from the lack of suitable
animal models. Since IgA1 equivalents are only found in humans and closely related apes, the use of
the species normally used in experimental research (mouse, rat, rabbit) will most likely fail to give
a realistic reflection of behaviour in humans. The other species differences noted earlier, such as
differences in the polymerisation state of serum IgA, tend to compound this problem. The mouse is
considered especially unsuitable for testing the function of human IgA because it lacks the equivalent
of human FcαRI. To circumvent this issue, mice transgenic for human CD89 have been generated and
Antibodies 2019, 8, 57 16 of 30
used widely as useful models for analysis of the function of human IgA [157,158]. Another notable
milestone in creation of useful mouse models was the generation of a human IgA knock-in mouse [159].
6. Current landscape of IgA-Based Therapeutics
6.1. Comparisons of IgG and IgA mAbs in Cancer Therapy
Traditional cancer therapies of removal surgery or radiation for elimination of tumour cells in
localised tumours and chemotherapy for metastatic tumours, while effective, are very aggressive
procedures. With the development of proteomic, genomic, and bioinformatics approaches, it became
possible to better characterise cancer cells and identify the proteins expressed at their surface.
Thus targeting of tumour cells by antibodies directed to tumour antigens, such as glycoproteins,
growth factors, cluster of differentiation (CD) antigens, is now an established treatment option [160].
Of the several therapeutic antibodies used in cancer treatment, some are used in solid tumours,
targeting specific antigens such as the epidermal growth factor receptor (EGFR) found in colorectal
cancer, or the human epidermal growth factor 2 (HER2) associated with breast cancer [161].
More “liquid” tumours such leukaemias and lymphomas have also been successfully treated.
For example, B-cell lymphomas have been treated with anti-CD20 mAbs [162]. Indeed, Rituximab,
an anti-CD20 antibody, was the first monoclonal antibody approved for cancer therapy in 1997, being
followed by several others, including Cetuximab (anti-EGFR) and Trastuzumab (anti-HER2), all of the
IgG isotype [163].
These mAbs work in different ways, with anti-CD20 mAb inducing apoptosis and sensitising
tumour cells for chemotherapy, anti-HER2 inhibiting intracellular pathways involved in cancer
progression, and anti-EGFR binding to growth factor receptors and blocking cancer cell
proliferation [164–166]. However, their performance will often depend on the expression levels
of the antigen on the tumour cells and can be affected by mutations in downstream pathways. Being of
the IgG subclass, these mAbs are able to activate the complement pathway and interact with Fcγ
receptors, eliminating tumours by cell lysis or targeting tumour cells for elimination by immune cells.
There has been debate regarding which subset of immune cells is more important for mAb therapy,
with natural killer (NK) cells seen for a long time as the main effectors, promoting apoptosis of tumour
cells [167]. Macrophages, and to a lesser extent monocytes, were also recognised for their phagocytosis
ability towards tumour cells coated with antibodies [168], while neutrophils were associated with
tumour regression, even in the absence of mAbs [169]. Neutrophils, besides secreting cytotoxic
agents, can lead to necrotic and autophagic tumour cell death, and can be recruited in large numbers,
especially upon stimulation with granulocyte-colony stimulating factor (G-CSF) and granulocyte
macrophage-colony stimulating factor (GM-CSF) [170,171]. The importance of neutrophils in tumour
clearance was shown in a B-cell lymphoma mice model, where anti-CD20 mAb was less effective when
neutrophils were depleted [172]. Since neutrophils do not easily recognise tumour cells, the use of
mAbs is important to establish this interaction. However, the high-affinity IgG Fc receptor FcγRI is
only expressed in neutrophils upon G-CSF stimulation, and besides the numerous side effects of the
stimulation, this therapeutic strategy did not lead to significant clinical responses when using IgG
mAbs [173–176].
IgA, together with its receptor FcαRI (CD89), create another possibility for new therapies focused
on the activation of FcαRI-expressing cells. Both FcαRI and FcγRI associate with FcR γ chain,
but FcαRI may create stronger electrostatic interactions with the FcR γ chain promoting a more stable
interaction [177]. Besides, binding to FcαRI promotes release of leukotriene B4 (LTB4), which acts as
a chemoattractant for neutrophils. Therefore, targeting this receptor leads to additional neutrophil
migration to tumour sites [80]. Although FcαRI expression in neutrophils is lower than that of Fcγ
receptors naturally expressed in these cells (FcγRIIa and FcγRIIIb), binding of IgA or IgG to neutrophils
is similar, which suggests a more stable binding by IgA and a higher efficiency at triggering neutrophils
than IgG [178]. For instance, the use of an IgA anti-Ep-CAM mAb was shown to kill colon carcinoma
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cells, unlike the IgG1 mAb counterpart [179]. Similar results were shown for the anti-EGFR mAb,
with the IgA being superior at recruiting polymorphonuclear cells than the IgG subtype [180].
Another alternative to target FcαRI consists in the use of bispecific antibodies (BsAb). By virtue
of combining two distinct antigen binding capabilities, BsAb are able to target tumours and recruit
immune cells, such as neutrophils, leading to tumour cell killing by antibody-dependent cellular
cytotoxicity mechanisms [181]. The use of a BsAb against both HER2 and FcαRI (namely anti-HER2 ×
FcαRI) efficiently eliminated breast carcinoma cells by neutrophil accumulation, unlike the equivalent
FcγRI-directed BsAb (anti-HER2 × FcγRI) [182]. The same was observed for CD20 antibodies, where
IgG Abs or FcγRI and FcγRIII-directed BsAbs (anti-CD20 × FcγRI or FcγRIII) showed no ability to kill
malignant B cells, whereas the equivalent FcαRI BsAb promoted malignant B cell killing via neutrophil
activation [183]. Another study showed that the BsAb anti-HLA II × FcαRI was effective in recruiting
polymorphonuclear cells against human B cell malignancies [184].
For a long time, in vivo studies on IgA and FcαRI cancer therapies were impaired by the lack of
FcαRI in mouse. However, the development of FcαRI transgenic mice has overcome that barrier [157].
Additionally, the study of mouse IgAs in interaction with FcαRI has been hampered due to the poor
binding of mouse IgA to the human FcαRI, but the knock-in of human IgA into mice (Cα1 gene
knock-in) has made possible the generation of antigen-specific human IgA mAbs in mice [159]. The use
of these animal models showed that anti-CD20 IgA mAbs can effectively prevent B cell lymphoma
development by recruiting FcαRI-expressing immune cells [67,185]. Likewise, IgA2 anti-EGFR was
proved to be more efficient than Cetuximab (IgG format) against tumour cells in a FcαRI transgenic
mice model [138]. In addition to the anti-tumour response of IgA1 anti-HER2 mAb, it was shown that
the introduction of an albumin binding domain allows the interaction with the neonatal Fc receptor
(FcRn), which is used for IgG and albumin recycling in the serum, leading to an increase of the
IgA half-life without compromising its anti-tumour activity in vivo [141]. As mentioned previously,
the half-life of IgA can also be extended by decreasing clearance by ASGPR in the liver, which can
be achieved by sialylation of the IgA glycans [138]. A higher sialylation of the N-glycans in the IgA
anti-HER2 did not interfere in the anti-tumour response and lead to the decrease in tumour growth in
FcαRI transgenic mice, while increasing the antibody half-life [140]. In another study, the removal of
two glycosylation sites and two free cysteines, together with a stabilised HC and LC linkage, created a
new IgA2 anti-EGFR mAb with a longer half-life than the wild-type antibody, and higher efficacy due
to Fab-mediated effects and interaction with myeloid cells expressing FcαRI [139].
6.2. IgA mAbs in Treating or Preventing Infections
Several anti-infective mAbs of the IgG isotype are approved to combat infectious diseases, namely,
Palivizumab against respiratory syncytial virus, Raxibacumab and Obiltoxaximab against anthrax,
and Bezlotoxumab to combat Clostridium difficile [186].
As the most abundant antibody at the mucosal surfaces, IgA has the important role of detecting
and alerting the immune system to pathogens, whilst not responding to commensal bacteria and
environmental antigens, representing an important means to combat infectious diseases. IgA antibodies
were shown to be effective against tuberculosis infection in a mouse model. The passive intranasal
inoculation with a mouse IgA mAb against the α-crystallin antigen of Mycobacterium tuberculosis led
to a significant decrease in bacteria in the lungs, when either monomeric or polymeric forms of the
antibody were used. Despite the transitory protective effect, probably due to the fast degradation of
the administered IgA, this antibody was shown to combat early infection in the lungs, with potential
use for immunoprophylaxis in immunocompromised individuals at risk of tuberculosis infection [187].
In a later study, the use of a human IgA1 against M. tuberculosis showed that the protective effect of the
passive inoculation is dependent on the presence of FcαRI, being observed only in mice transgenic for
human FcαRI [188]. These results suggest that the interaction between the human IgA1 and FcαRI on
neutrophils and macrophages allows binding and elimination of M. tuberculosis. In the same study,
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in vitro infection of human whole blood or isolated monocytes by M. tuberculosis was reduced in the
presence of specific IgA1 [188].
The importance of interaction with FcαRI was also shown for control of Escherichia coli infection,
which when recognised by human serum IgA, can be efficiently phagocytised by FcαRI-expressing
cells [189]. This ability of IgA to bind FcαRI and directly induce neutrophil migration was shown to
be an important defense mechanism against several other bacteria, such as Streptococcus pneumonia,
Staphylococcus aureus, Porphyromonas gingivalis, Candida albicans, Bordetella Pertussis, and Neisseria
meningitidis [81,190–194].
The immune exclusion ability of IgA was also shown in the context of Salmonella typhimurium
infection, where mice were orally challenged with the bacteria alone or the bacteria complexed with
plasma-derived IgA and IgM [195]. Reduced bacteria dissemination was reported in mice exposed to
the IgA/IgM immune complexes, mainly for antibodies coupled with the secretory component (SC),
whilst IgG was unable to form immune complexes and consequently protect against S. typhimurium
spread in gut immune structures [195]. Besides, oral administration of SIgA/M prior to intragastric
S. typhimurium challenge is sufficient to protect mice from infection [196]. Despite the studies showing
the potency of these IgA antibodies to prevent bacterial infections, all the existing immunoglobulin
preparations used clinically for replacement therapy contain only IgG [197].
Passive immunisation with monomeric IgA can also be applied for viral infections. The use of
vaccines against influenza virus showed the emergence of both IgA and IgG in nasal washes, but it was
difficult to establish the importance of these antibodies individually [198,199]. Passive immunisation
with IgG or pIgA by intravenous injection culminated in specific transport of these antibodies into
nasal secretions [200]. However, high doses of IgG anti-influenza have to be injected in order to detect
its presence in mice nasal secretions, and even higher doses are needed to decrease viral shedding [201].
On the other hand, administration of polymeric IgA at levels normally found in convalescent mice is
enough to eliminate nasal viral shedding. Therefore, SIgA prevents infection of the upper respiratory
tract, while serum IgG is important as a secondary response, acting at a later stage by detecting viruses
that escaped IgA neutralisation and preventing lung infection [201]. A study using rotavirus showed
that mice can be protected from infection when IgA mAb against the viral capsid was systemically
administrated, but not when added to the intestinal lumen, showing the importance of transcytosis as
a way of viral inactivation [65].
Passive immunisation was also tested on simian models of HIV infection. Intrarectal administration
of IgG and dimeric IgA specific for the viral envelope showed that dimeric IgA provided the best
protection in vivo upon SHIV infection in rhesus monkeys [202]. The protection conferred by dimeric
IgA was suggested to be related to its ability to directly neutralise the virus and to form complexes
that prevented free viruses crossing the epithelial cell layer. Based on the interaction of SIgA with
mucosal microfold (M) cells, another study explored the transport of an HIV antigen for immunisation
via this mechanism. SIgA bound to the HIV antigen was delivered orally and transported across the
epithelial barrier to be captured by dendritic cells, starting mucosal and systemic immune responses
that ultimately showed to be protective against infection by a recombinant virus expressing the HIV
antigen [203]. Therefore, infection can be impaired by several IgA associated mechanisms, either by
immune exclusion, intracellular inactivation, or recognition and activation of the immune system.
6.3. FcαRI Blocking Agents
Targeting FcαRI can be used as a strategy to combat autoimmune diseases, to inhibit IgG-induced
phagocytosis or IgE-mediated allergic diseases. In autoimmune diseases, binding of IgA to FcαRI
leads to enhanced activation of immune cells, and therefore, blocking this interaction can be beneficial
to decrease tissue damage. The exposure of neutrophils to IgA immune complexes obtained from
rheumatoid arthritis patients leads to in vitro release of neutrophil extracellular traps, which consist
of web-like structures made of DNA and proteins that, despite capturing pathogens, are associated
with tissue damage. However, the use of an anti-FcαRI mAb (MIP8a) was shown to successfully
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decrease neutrophil extracellular traps formation [204]. The same anti-FcαRI mAb was shown to
prevent IgA autoantibodies inducing tissue damage in an ex vivo human skin model for linear IgA
bullous disease [97]. Beyond mAbs, peptides that bind to the interaction sites of IgA and FcαRI could
also inhibit IgA-induced neutrophil migration, having the advantage to be able to penetrate into the
skin, which opens up the possibility of using them for skin autoimmune disease therapy [96].
Besides IgA, other antibodies can start immune responses that, when exacerbated, can be harmful,
culminating in extensive inflammation or allergies. Binding of FcαRI by monomeric IgA is known
for its anti-inflammatory nature through ITAMi signalling in effector cells [205]. Therefore, the
IgA–FcαRI interaction can be explored as a tool to alleviate inflammation and further tissue damage
caused by other antibodies. Using an allergy mice model, it was possible to show a decrease in
airway inflammation upon crosslinking of FcεRI with IgE immune complexes in a FcαRI transgenic
mice treated with the anti-FcαRI mAb A77 [206]. In another study, monomeric IgA was shown to
successfully abrogate arthritis in a FcαRI transgenic mice model where IgG anti-collagen was used to
cause rheumatoid arthritis [207]. Using a FcαRI transgenic mice model with glomerulonephritis and
obstructive nephropathy caused by accumulation of IgG immune complexes, the Fab A77 targeting
FcαRI was shown to be able to suppress inflammation [208]. It was also established that renal
inflammation induced by different agents can be alleviated by the use of Fab fragments that target
FcαRI (MIP8a) or monomeric IgA [209,210]. Therefore, targeting FcαRI either through IgA binding
or the use of specific antibodies, can be used as a strategy to initiate anti-inflammatory responses in
inflammatory diseases that involve myeloid cells.
7. Summary and Conclusions
The structural features of IgA impart this Ab class with unique functional capabilities, which are
yet to be fully harnessed for therapeutic benefit. Increasing numbers of mAbs have been approved
for clinical use in the last few years, and many more are currently undergoing clinical trial [211,212].
Recent examples tend to be humanised or fully human, but invariably of the IgG isotype. To date,
no antibodies of the IgA isotype are known to be going through clinical trials. Regarding BsAbs,
only a very few have been approved for use in the United States, while several await approval or
are in preclinical and clinical trials [213]. In this context, FcαRI-targeting BsAbs are yet to reach this
stage, indicating that further effort is required before the potential of IgA/FcαRI related therapies
can be realised. As that point approaches, interest will undoubtedly turn to options for delivery
to mucosal sites. Progress with topical application of nebulised Igs in the lungs of experimental
animals [214,215] suggest that suitable strategies for mucosal delivery of mAbs in humans may appear,
and we can anticipate that IgA-based mAbs will emerge as an important new arm of the arsenal of
therapeutic mAbs.
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